Andrew Lin Ji, MD
Dermatology · New York
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Icahn School of Medicine at Mount Sinai · 2,809 clinicians in this group
Hospitals listed: Mount Sinai Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ji’s office at (212) 241-8234 to ask if they take your plan before you enroll.
California Medical Board record
Licence A137943 · Delinquent
Licence status: Delinquent · since 2015 · expires 2023-01-31 · Cornell University Medical College.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mount Sinai HospitalNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Mount Sinai Health System, which runs 5 hospitalsHome of Tisch Cancer Institute, a National Cancer Institute designated cancer centrePatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.9 (11 to 15) · 878 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.473, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.513, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.9 (3 to 5.1) · 878 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Mount Sinai Hospital
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 1 worse of 8 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.9 (11 to 15) · 878 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.473 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.513 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.9 (3 to 5.1) · 878 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.56 (0.9 to 2.21) · 4,503 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.88 to 1.18) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 172.14 (136.78 to 207.5) · 260 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 168 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 139 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.9 · 785 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 774 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.8 · 589 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.2 · 10,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.08 (0 to 0.24) · 19,045 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.36 (0.21 to 0.52) · 20,760 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.47 (3.23 to 5.72) · 7,869 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.36 (0.41 to 2.3) · 3,840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.62 (0.77 to 2.47) · 7,428 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.64 (5.02 to 10.27) · 3,845 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.23 (2.36 to 6.09) · 4,008 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.19 (0 to 2.45) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.93 (0.63 to 1.23) · 15,577 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.7 · 621 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.718 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.654 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.779 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.813 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 385 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 1,625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.7 · 236 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 21.5 · 883 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 37.6 · 760 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.6 · 1,228 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.2 · 669 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 371 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.3 to 16.1) · 681 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,157 cases | No different | Jan 2024 – Dec 2024 |
What patients said (799 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$4,141
Medicare paid this office $4,141 for 45 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 22 | $2,113 | $78 |
| Short return visit (20+ min) | 11 | $517 | $47 |
Procedures Medicare counted
| Removal of skin lesions | 1-10 | None |
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
45 Original Medicare patients in 2024. Average age 68 · Under 65 27% · Women 69% · Also on Medicaid 76% · Health risk score 1.79. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 67% · Diabetes 33%.
The office billed $19,117, Medicare allowed $5,700 and paid $4,141; for 65 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 45 | 65 | 68 | 1.79 | $19,117 | $4,141 |
| 2023 | 22 | 39 | 71 | 2.14 | $10,010 | $1,826 |
| 2022 | 83 | 253 | 73 | 1.66 | $72,484 | $19,905 |
| 2021 | 24 | 117 | 76 | 1.92 | $16,519 | $3,046 |
| 2020 | 57 | 171 | 73 | 1.52 | $28,923 | $5,505 |
| 2019 | 53 | 274 | 73 | 1.19 | $20,312 | $6,169 |
| 2018 | 16 | 43 | 74 | 1.76 | $5,050 | $1,498 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 6 services
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 22 | $8,772 | $110 |
| Return visit (30+ min) | 17 | $2,881 | $115 |
| New patient visit (45+ min) | 13 | $1,887 | $145 |
| Destruction of precancer skin growth, 1 growth | 15 | $949 | $45 |
| Short return visit (20+ min) | 13 | $941 | $67 |
| Destruction of precancer skin growth, 2-14 growths | 12 | $306 | $7 |
2020: 2 services
| Short return visit (20+ min) | 26 | $1,078 | $37 |
| Short return visit (20+ min) | 19 | $906 | $41 |
2019: 5 services
| Short return visit (20+ min) | 37 | $2,105 | $42 |
| Destruction of precancer skin growth, 1 growth | 21 | $1,023 | $38 |
| Destruction of skin growth, 1-14 growths | 13 | $940 | $63 |
| New patient visit (30+ min) | 15 | $878 | $59 |
| Destruction of precancer skin growth, 2-14 growths | 17 | $237 | $2 |
Medicaid work
$1,354 in 2022
Medicaid paid $1,354 for 15 billed services this clinician did in 2022, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 15 | $1,354 |
| 2022 | 15 | 1 | 15 | $1,354 |
| 2021 | 559 | 2 | 59 | $36,802 |
| 2020 | 563 | 3 | 47 | $33,804 |
| 2019 | 499 | 2 | 43 | $26,755 |
See the largest Medicaid services in earlier years
2021
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 364 | $28,580 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 195 | $8,222 |
2020
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 267 | $22,695 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 283 | $10,004 |
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 13 | $1,105 |
2019
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 283 | $21,909 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 216 | $4,846 |
Drugs they prescribed that Part D paid
$60,183
Pharmacies billed $60,183 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 113) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
93 generic and 20 brand-name prescriptions · $60,183 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ketoconazole | 13 | $279 | $21 |
| Triamcinolone Acetonide | 16 | $251 | $16 |
Year by year
| 2024 | 113 | 38 | 0% (0) | 18% | $60,183 |
| 2023 | 129 | 33 | 0% (0) | 18% | $171,763 |
| 2022 | 141 | 49 | 0% (0) | 11% | $7,313 |
| 2021 | 115 | 38 | 0% (0) | 12% | $8,107 |
| 2020 | 166 | 48 | 0% (0) | 11% | $6,436 |
| 2019 | 79 | 33 | 0% (0) | None | $4,900 |
| 2018 | 27 | 13 | 0% (0) | None | $1,850 |
| 2015 | 29 | 14 | None | None | $1,050 |
| 2014 | 30 | None | None | None | $1,164 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Clobetasol Propionate | 16 | $2,150 | $134 |
| Ketoconazole | 18 | $633 | $35 |
| Triamcinolone Acetonide | 19 | $245 | $13 |
2022: 3 drugs
| Clobetasol Propionate | 16 | $1,108 | $69 |
| Fluocinonide | 17 | $1,028 | $60 |
| Triamcinolone Acetonide | 31 | $339 | $11 |
2021: 4 drugs
| Fluocinonide | 35 | $2,726 | $78 |
| Clobetasol Propionate | 12 | $1,605 | $134 |
| Betamethasone Dipropionate | 11 | $1,471 | $134 |
| Triamcinolone Acetonide | 18 | $200 | $11 |
2020: 6 drugs
| Clindamycin Phosphate | 13 | $1,161 | $89 |
| Fluocinonide | 23 | $1,055 | $46 |
| Doxycycline Hyclate | 12 | $746 | $62 |
| Triamcinolone Acetonide | 38 | $636 | $17 |
| Mupirocin | 16 | $95 | $6 |
| Hydrocortisone | 12 | $40 | $3 |
2019: 2 drugs
| Triamcinolone Acetonide | 21 | $369 | $18 |
| Hydrocortisone | 13 | $66 | $5 |
Money from drug and device companies
$27 in 2025
| 2025 | 1 | 1 | None | $27 |
| 2023 | 4 | 4 | None | $125,173 |
| 2022 | 3 | 5 | None | $125,070 |
| 2020 | 1 | 1 | None | $25 |
| 2019 | 1 | 1 | None | $15 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Galderma Laboratories L.P. | Nemluvio | $27 | 1 payment
|
See the published payment
| Galderma Laboratories L.P. | Meals · 2025-02-18 | Nemluvio | $27 |
See earlier years (2023, 2022, 2020, 2019)
2023: $125,173
| Regeneron Pharmaceuticals | None | $125,000 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $142 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $16 | 1 payment
|
| Pfizer | None | $15 | 1 payment
|
2022: $125,070
| Regeneron Pharmaceuticals | None | $125,000 | 1 payment
|
| Abbvie | Skyrizi | $58 | 3 payments
|
| LEO Pharma | Adbry | $12 | 1 payment
|
2020: $25
| AbbVie | Skyrizi | $25 | 1 payment
|
2019: $15
| AbbVie | Humira | $15 | 1 payment
|
Professional record
- NPI
- 1265843460
- Licence
- CA A137943, NY 310434California A137943: Delinquent · expires 2023-01-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Student in a training program (390200000X)
- Mailing address
- 5 E 98th St, New York, NY, 10029
- NPI first listed
- 2014-05-11
- NPI last updated
- 2021-09-03
- NPI record certified
- 2021-09-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 420 E 70th St Apt 15g, New York, NY, 10021 · 300 Pasteur Dr, Stanford, CA, 94305